[go: up one dir, main page]

GT200500378A - Macrolidos - Google Patents

Macrolidos

Info

Publication number
GT200500378A
GT200500378A GT200500378A GT200500378A GT200500378A GT 200500378 A GT200500378 A GT 200500378A GT 200500378 A GT200500378 A GT 200500378A GT 200500378 A GT200500378 A GT 200500378A GT 200500378 A GT200500378 A GT 200500378A
Authority
GT
Guatemala
Prior art keywords
compounds
methods
macrolidos
antiprotozoar
antibacterial
Prior art date
Application number
GT200500378A
Other languages
English (en)
Inventor
Louis Stanley Chupak
Mark Edward Flanagan
Takushi Kaneko
Thomas Victor Magee
Mark Carl Noe
Usa Reilly
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500378(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of GT200500378A publication Critical patent/GT200500378A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Tires In General (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS MACRÓLIDOS PER SE, COMO SE MUESTRAN A CONTINUACIÓN Y SE DEFINEN EN LA MEMORIA, Y SU USO, POR EJEMPLO COMO AGENTES ANTIBACTERIANOS Y ANTIPROTOZOARIOS EN ANIMALES, INCLUYENDO SERES HUMANOS. TAMBIEN SE DESCRIBEN MÉTODOS PARA PREPARAR LOS COMPUESTOS, PRODUCTOS INTERMEDIOS Y SUS COMPOSICIONES FARMACÉUTICAS, Y MÉTODOS PARA TRATAR O PREVENIR LA ENFERMEDAD POR ADMINISTRACIÓN DE LOS COMPUESTOS A LOS SUJETOS QUE LO NECESITEN.
GT200500378A 2004-12-21 2005-12-20 Macrolidos GT200500378A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63809704P 2004-12-21 2004-12-21
US71753005P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
GT200500378A true GT200500378A (es) 2006-11-28

Family

ID=35809765

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500378A GT200500378A (es) 2004-12-21 2005-12-20 Macrolidos

Country Status (35)

Country Link
US (1) US7462600B2 (es)
EP (2) EP1836211B1 (es)
JP (1) JP4111994B1 (es)
KR (1) KR100897678B1 (es)
CN (1) CN101120011A (es)
AP (1) AP2007004026A0 (es)
AR (1) AR052824A1 (es)
AT (1) ATE459633T1 (es)
AU (1) AU2005317735B2 (es)
BR (1) BRPI0519135A2 (es)
CA (1) CA2591746A1 (es)
CR (1) CR9202A (es)
DE (1) DE602005019786D1 (es)
DK (1) DK1836211T3 (es)
EA (1) EA011281B1 (es)
ES (1) ES2339871T3 (es)
GE (1) GEP20094834B (es)
GT (1) GT200500378A (es)
HN (1) HN2005036113A (es)
HR (1) HRP20100253T1 (es)
IL (1) IL183661A0 (es)
MA (1) MA29108B1 (es)
MX (1) MX2007007598A (es)
NL (1) NL1030713C2 (es)
NO (1) NO20073367L (es)
PE (1) PE20060948A1 (es)
PL (1) PL1836211T3 (es)
PT (1) PT1836211E (es)
SI (1) SI1836211T1 (es)
TN (1) TNSN07233A1 (es)
TW (1) TW200626608A (es)
UA (1) UA85937C2 (es)
UY (1) UY29285A1 (es)
WO (1) WO2006067589A1 (es)
ZA (1) ZA200705108B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
WO2007025098A2 (en) 2005-08-24 2007-03-01 Rib-X Pharmaceuticals, Inc. Triazole compounds and methods of making and using the same
JP4468487B1 (ja) * 2007-03-13 2010-05-26 ファイザー・プロダクツ・インク エリスロマイシンをベースとするマクロライド
EP2136806A4 (en) * 2007-03-21 2011-11-23 Creative Antibiotics Sweden Ab METHOD AND MEANS FOR PREVENTING AND SUPPRESSING TYPE III SECRETION IN INFECTIONS BY GRAM-NEGATIVE BACTERIA
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
WO2009053259A1 (en) * 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
CN101903382B (zh) 2007-12-21 2012-11-28 弗·哈夫曼-拉罗切有限公司 杂环抗病毒化合物
US8865662B2 (en) 2009-08-13 2014-10-21 Basilea Pharmaceutica Ag Macrolides and their use
JP5711352B2 (ja) * 2010-03-22 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライドの結晶形、およびその使用
CN106974913A (zh) * 2011-04-12 2017-07-25 美国卫生和人力服务部 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂
CN102558047B (zh) * 2011-12-14 2013-10-30 天津药物研究院药业有限责任公司 3-甲基喹啉的制备方法
IN2014DN08939A (es) 2012-03-27 2015-05-22 Cempra Pharmaceuticals Inc
US9611224B2 (en) 2012-07-13 2017-04-04 Hoffmann-La Roche Inc. Antiproliferative benzo [B] azepin-2-ones
KR101663864B1 (ko) * 2013-04-19 2016-10-07 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 약학조성물
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
CN103739643A (zh) * 2013-12-30 2014-04-23 华东理工大学 利用分子印迹技术对红霉素进行回收分离纯化的方法
CN104230891B (zh) * 2014-08-27 2016-03-30 于宗光 一种托匹司他的制备方法
JP2019533669A (ja) 2016-10-04 2019-11-21 バイオファーマティ ソシエテ アノニム 抗菌活性を有するケトライド
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
AU2020288559C1 (en) * 2019-06-04 2025-07-24 Hager Biosciences, Llc Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
CN111793022A (zh) * 2020-04-27 2020-10-20 滁州拜奥生物科技有限公司 一种3-甲基喹啉的制备方法
JP2025530768A (ja) * 2022-09-01 2025-09-17 ヘイガー バイオサイエンシズ，エルエルシー 神経疾患および精神疾患の治療のための、オレキシン受容体およびカッパオピオイド受容体に対する二重調節剤としてのピラゾール誘導体およびイミダゾール誘導体、組成物、ならびに治療法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653899A (en) 1952-04-14 1953-09-29 Lilly Co Eli Erythromycin, its salts, and method of preparation
US2823203A (en) 1954-06-24 1958-02-11 Abbott Lab Method of producing substantially pure erythromycin a
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
US5075289A (en) 1988-06-07 1991-12-24 Abbott Laboratories 9-r-azacyclic erythromycin antibiotics
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5523399A (en) 1991-12-27 1996-06-04 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
FR2727969B1 (fr) 1994-12-09 1997-01-17 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5747466A (en) 1995-11-08 1998-05-05 Abbott Laboratories 3-deoxy-3-descladinose derivatives of erythromycins A and B
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
JP2000509712A (ja) 1996-05-07 2000-08-02 アボツト・ラボラトリーズ ６―ｏ―置換エリスロマイシン及びその製造方法
US5750510A (en) 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
FR2748746B1 (fr) 1996-05-14 1998-08-14 Hoechst Marion Roussel Inc Nouveau procede d'isomerisation du radical methyle en 10 de derives de l'erythromycine
US6271255B1 (en) 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
FR2751656B1 (fr) 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ATE296308T1 (de) 1996-09-04 2005-06-15 Abbott Lab 6-o-substituierte ketoliden mit antibakteriellen wirkung
US5804565A (en) 1996-09-24 1998-09-08 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
WO1998023628A1 (fr) * 1996-11-27 1998-06-04 Taisho Pharmaceutical Co., Ltd. Derives de l'erythromicine a
US6140479A (en) 1997-03-24 2000-10-31 Taisho Pharmaceuticals Co., Ltd. Erythromycin a derivatives
AU6932098A (en) 1997-05-09 1998-12-08 Pfizer Products Inc. Erythromycin derivatives
US20020025937A1 (en) 2000-03-20 2002-02-28 Yong-Jin Wu 9-oxime erythromycin derivatives
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
ZA987689B (en) 1997-09-02 1999-02-24 Abbott Lab 3-descladinose 6-O substituted erythromycin derivatives
US6034069A (en) 1997-09-30 2000-03-07 Abbott Laboratories 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
PA8461401A1 (es) 1997-10-29 2000-05-24 Pfizer Prod Inc Derivados de eritromicina triciclicos
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
AU9649598A (en) 1997-10-29 1999-05-17 Taisho Pharmaceutical Co., Ltd. Erythromycin a, 11,12-carbamate derivatives
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
AP9801420A0 (en) 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
EP0941998B1 (en) 1998-03-03 2004-09-01 Pfizer Products Inc. 3,6-ketal macrolide antibiotics
US5955440A (en) 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
US6248719B1 (en) 1998-06-03 2001-06-19 Pfizer Inc Tricyclic 3-keto derivatives of 6-O-methylerthromycin
JP4573925B2 (ja) 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
CZ20011512A3 (cs) 1998-11-03 2001-09-12 Pfizer Products Inc. Nová makrolidová antibiotika
US6262030B1 (en) 1998-11-03 2001-07-17 Pfizer Inc. Erythromycin derivatives
TR200102129T2 (tr) 1998-12-10 2002-01-21 Pfizer Products Inc. Karbamat ve karbazat ketolid antibiyotikleri.
KR20020002380A (ko) 1999-01-27 2002-01-09 실버스타인 아써 에이. 케톨라이드 항생물질
US6054435A (en) 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
CN1373767A (zh) * 1999-04-16 2002-10-09 奥索-麦克尼尔药品公司 酮式大环内酯抗菌剂
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
ATE340183T1 (de) 1999-04-16 2006-10-15 Kosan Biosciences Inc Antiinfektiöse makrolidderivate
US20020077302A1 (en) 1999-04-23 2002-06-20 Yong-Jin Wu Tricyclic erythromycin derivatives
US20020061857A1 (en) 1999-04-23 2002-05-23 Yong-Jin Wu 9-amino-3-oxo erythromycin derivatives
US6355620B1 (en) 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
HK1045523A1 (zh) 1999-05-24 2002-11-29 辉瑞产品公司 13-甲基红霉素衍生物
JP2001072669A (ja) 1999-09-07 2001-03-21 Showa Kako Kk ７−クロロ−２，４（１ｈ，３ｈ）−キナゾリンジオンの製造方法
US6569836B2 (en) 1999-12-02 2003-05-27 Abbott Laboratories 6-O-alkyl-2-nor-2-substituted ketolide derivatives
EP1114826A3 (en) 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
EP1122261A3 (en) 2000-01-31 2001-09-26 Pfizer Products Inc. 13 and 14-membered antibacterial macrolides
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
EP1146051A3 (en) 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A derivatives
US20020061856A1 (en) 2000-04-24 2002-05-23 Yong-Jin Wu Novel tricyclic erythromycin derivatives
ES2222966T3 (es) 2000-06-30 2005-02-16 Pfizer Products Inc. Macrolidos antibioticos.
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
DE60124594T2 (de) 2000-12-21 2007-10-04 Glaxo Group Ltd., Greenford Makrolidantibiotika
US20020132782A1 (en) 2001-01-18 2002-09-19 Zhenkun Ma 9-amino erythromycin derivatives with antibacterial activity
JP4509553B2 (ja) 2001-07-03 2010-07-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗菌活性を有するｃ１２修飾エリスロマイシンマクロライドおよびケトライド
WO2005070918A1 (en) 2002-05-13 2005-08-04 Enanta Pharmaceuticals, Inc. Process for the preparation of t-11 bicyclic erythromycin derivatives
US7064110B2 (en) 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
WO2004094407A1 (ja) 2003-04-21 2004-11-04 Daiichi Pharmaceutical Co. Ltd. ５員複素環誘導体
BRPI0513903A (pt) 2004-07-28 2008-05-20 Ranbaxy Lab Ltd derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
WO2006046112A2 (en) 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
GB0424951D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
JP2008522978A (ja) 2004-12-07 2008-07-03 エナンタ ファーマシューティカルズ インコーポレイテッド ３，６−ビシクロライド
US7312201B2 (en) 2004-12-13 2007-12-25 Enanta Pharmaceuticals, Inc. Tetracyclic bicyclolides
US7291602B2 (en) 2004-12-13 2007-11-06 Enanta Pharmaceuticals, Inc. 11,12-lactone bicyclolides

Also Published As

Publication number Publication date
CA2591746A1 (en) 2006-06-29
ATE459633T1 (de) 2010-03-15
US20060135447A1 (en) 2006-06-22
DE602005019786D1 (de) 2010-04-15
AP2007004026A0 (en) 2007-06-30
IL183661A0 (en) 2007-09-20
TNSN07233A1 (fr) 2008-11-21
AR052824A1 (es) 2007-04-04
KR100897678B1 (ko) 2009-05-14
AU2005317735B2 (en) 2009-06-04
MA29108B1 (fr) 2007-12-03
PL1836211T3 (pl) 2010-07-30
TW200626608A (en) 2006-08-01
DK1836211T3 (da) 2010-05-17
NL1030713A1 (nl) 2006-06-22
EA200701113A1 (ru) 2007-12-28
WO2006067589A1 (en) 2006-06-29
HRP20100253T1 (hr) 2010-06-30
PE20060948A1 (es) 2006-10-11
MX2007007598A (es) 2007-07-25
KR20070089191A (ko) 2007-08-30
AU2005317735A1 (en) 2006-06-29
JP2008524319A (ja) 2008-07-10
NO20073367L (no) 2007-09-05
CR9202A (es) 2007-07-16
UA85937C2 (uk) 2009-03-10
BRPI0519135A2 (pt) 2008-12-23
EP2233493A1 (en) 2010-09-29
SI1836211T1 (sl) 2010-04-30
ZA200705108B (en) 2009-01-28
PT1836211E (pt) 2010-04-08
US7462600B2 (en) 2008-12-09
UY29285A1 (es) 2006-07-31
EP1836211B1 (en) 2010-03-03
CN101120011A (zh) 2008-02-06
ES2339871T3 (es) 2010-05-26
EA011281B1 (ru) 2009-02-27
GEP20094834B (en) 2009-11-25
NL1030713C2 (nl) 2006-12-12
HN2005036113A (es) 2010-12-06
JP4111994B1 (ja) 2008-07-02
EP1836211A1 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
GT200500378A (es) Macrolidos
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
PA8570901A1 (es) Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
PA8622401A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos
ECSP088102A (es) Compuestos para el tratamiento de infecciones bacterianas resistentes a múltiples fármacos
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
PA8592301A1 (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
UY31539A1 (es) Agentes antelminticos y su uso
SV2004001691A (es) Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen compuestos y sus usos
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
GT200500307A (es) Compuestos quimicos
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
PA8803201A1 (es) Derivados acidos de cicloalquilamino
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
NI201100183A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5 - disustituida